Search Results - "Ceresola, E"

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients by Gianotti, N., Canducci, F., Galli, L., Cossarini, F., Salpietro, S., Poli, A., Nozza, S., Spagnuolo, V., Clementi, M., Sampaolo, M., Ceresola, E.R., Racca, S., Lazzarin, A., Castagna, A.

“…In this single-centre, retrospective study, we analyzed data of 194 patients receiving antiretroviral therapy with <50 human immunodeficiency virus (HIV) RNA…”
Get full text

Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption by Canducci, F., Barda, B., Ceresola, E., Spagnuolo, V., Sampaolo, M., Boeri, E., Nozza, S., Cossarin, F., Galli, A., Gianotti, N., Castagna, A., Lazzarin, A., Clementi, M.

“…The objective of this study was to address the evolution of human immunodeficiency virus type 1 (HIV-1) mutations resistant to the integrase inhibitor…”
Get full text

Therapeutic Strategies and Clinical Outcome in Papillary Thyroid Microcarcinoma: A Multicenter Observational Study by Cecoli, F., Ceresola, E.M., Altrinetti, V., Cabria, M., Cappagli, M., Montepagani, A., Cuttica, C.M., Filippi, U., Saverino, D., Raffa, M., Caputo, M., Minuto, F., Giusti, M., Bagnasco, M.

“…Purpose: Papillary thyroid microcarcinoma (MPTC) has an excellent prognosis. We aimed to evaluate the evolution of therapeutic strategies over time and the…”
Get full text

A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves' disease: need to retarget the radiation committed dose to the thyroid by Schiavo, M, Bagnara, M C, Calamia, I, Bossert, I, Ceresola, E, Massaro, F, Giusti, M, Pilot, A, Pesce, G, Caputo, M, Bagnasco, M

Get full text

A study of the efficacy of radioiodine therapy with individualized dosimetry in Graves’ disease: Need to retarget the radiation committed dose to the thyroid by Schiavo, M., Bagnara, M. C., Calamia, I., Bossert, I., Ceresola, E., Massaro, F., Giusti, M., Pilot, A., Pesce, G., Caputo, M., Bagnasco, M.

“…Although Iodine-131 ( 131 |) therapy is fully validated for Graves’ disease (GD), there is debate about radioiodine amount to be administered (prescribed…”
Get full text

Thyrotropin receptor autoantibody measurement following radiometabolic treatment of hyperthyroidism: Comparison between different methods by Chiappori, A., Villalta, D., Bossert, I., Ceresola, E. M., Lanaro, D., Schiavo, M., Bagnasco, M., Pesce, G.

“…Background : TSH receptor antibodies (TRAb) play a crucial role in the pathogenesis of Graves’ disease (GD). The use of human recombinant TSH-receptor far…”
Get full text

A case-controlled study on the quality of life in a cohort of patients with history of differentiated thyroid carcinoma by Giusti, M, Sibilla, F, Cappi, C, Dellepiane, M, Tombesi, F, Ceresola, E, Augeri, C, Rasore, E, Minuto, F

“…Although quality of life (QoL) has become an important aspect of cancer rehabilitation, psychometric studies on thyroid cancer patients are rare. We performed…”
Get full text

Potential indications for somatostatin analogues: immune system and limphoproliferative disorders by Ferone, D, Resmini, E, Boschetti, M, Arvigo, M, Albanese, V, Ceresola, E, Pivonello, R, Albertelli, M, Bianchi, F, Giusti, M, Minuto, F

“…Among hormones and neuropeptides influencing the immune system, somatostatin seems to play a key role not only in inhibiting specific immune cell activities,…”
Get full text

In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir by Canducci, Filippo, Ceresola, Elisa Rita, Saita, Diego, Castagna, Antonella, Gianotti, Nicola, Underwood, Mark, Burioni, Roberto, Lazzarin, Adriano, Clementi, Massimo

“…The cross-resistance profiles of elvitegravir and dolutegravir on raltegravir-resistant variants is still controversial or not available in macrophages and…”
Get full text

Safety and efficacy of administering 0.2 mg of recombinant human TSH for two consecutive days as an adjuvant to therapy with low radioiodine doses in elderly out-patients with large nontoxic multinodular goiter by Giusti, M, Cappi, C, Santaniello, B, Ceresola, E, Augeri, C, Lagasio, C, Minuto, F

“…The aim of this study was to evaluate the efficacy of recombinant human TSH (rhTSH) as an adjuvant to radioiodine therapy for nontoxic multinodular goiter…”
Get more information

HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients: Virology by Gianotti, N, Canducci, F, Galli, L, Cossarini, F, Salpietro, S, Poli, A, Nozza, S, Spagnuolo, V, Clementi, M, Sampaolo, M, Ceresola, E R, Racca, S, Lazzarin, A, Castagna, A

“…In this single-centre, retrospective study, we analyzed data of 194 patients receiving antiretroviral therapy with <50 human immunodeficiency virus (HIV) RNA…”
Get full text

Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts by NOZZA, Silvia, CANDUCCI, Filippo, D'ARMINIO MONFORTE, Antonella, CASTAGNA, Antonella, GALLI, Laura, COZZI-LEPRI, Alessandro, ROSARIA CAPOBIANCHI, Maria, RITA CERESOLA, Elisa, NARCISO, Pasquale, LIBERTONE, Raffaella, CASTELLI, Paula, MOIOLI, Mariacristina

“…To investigate the value of tropism (determined by genotypic testing) to predict CD4 depletion in HIV-infected antiretroviral-naive patients with high CD4…”
Get full text